Blog
RSS FeedPosted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, ...
Posted by Michael Wonder on 30 Jul 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx for hidradenitis suppurativa (
23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec. ...
Posted by Michael Wonder on 28 Jul 2025
Drug giants targeting Australia’s PBS are paying tiny amounts of tax
28 July 2025 - Global pharmaceutical giants, including Pfizer and Johnson & Johnson, are paying a tiny fraction of the ...
Posted by Michael Wonder on 28 Jul 2025
Government continues to make medicines cheaper
28 July 2025 - The Albanese Government is making cheaper medicines even cheaper – with legislation being introduced to Parliament ...
Posted by Michael Wonder on 28 Jul 2025
Dupilumab for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (review of TA648)
23 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Jul 2025
Australia’s PBS must ‘absolutely’ be protected in trade talks, says Make America Healthy Again medical adviser Aseem Malhotra
26 July 2025 - The chief medical adviser to Make America Healthy Again campaign has defended Australia’s PBS, as the Trump ...
Posted by Michael Wonder on 25 Jul 2025
Lisocabtagene maraleucel in follicular lymphoma: mysterious study discontinuation
15 July 2025 - The BMS has not provided any study data suitable for early benefit assessment. It initiated a randomised ...
Posted by Michael Wonder on 21 Jul 2025
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
21 July 2025 - We have recommended the first under the tongue tablet immunotherapy shown to build long-term tolerance to allergens, ...
Posted by Michael Wonder on 20 Jul 2025
New and expanded cheaper medicines for severe and life-threatening conditions
20 July 2025 - Australians with post-transplant cytomegalovirus, breast, bile duct and urothelial cancer now have access to new and expanded ...
Posted by Michael Wonder on 20 Jul 2025
Amivantamab in combination with lazertinib for the first-line treatment of patients with advanced EGFR mutation positive non-small cell lung cancer
4 July 2025 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 18 Jul 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – March 2025 PBAC meeting
18 July 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the March 2025 PBAC ...
Posted by Michael Wonder on 18 Jul 2025
Outcome statement - June 2025 DUSC meeting
18 July 2025 - The outcome statement from the June 2025 DUSC meeting is now available. ...
Posted by Michael Wonder on 17 Jul 2025
Thousands more breast cancer patients to benefit from new NHS treatment
17 July 2025 - NICE approves ribociclib combination therapy to help prevent cancer returning in early stage disease. ...
Posted by Michael Wonder on 17 Jul 2025
Pfizer broadside on PBS productivity amid pharma tariff fears
16 July 2025 - Multinational conglomerate Pfizer has accused the PBS of “undervaluing” medical products in a submission to the ...
Posted by Michael Wonder on 17 Jul 2025
Labor and Coalition in lockstep as Trump threatens to pull pharma tariffs forward
16 July 2025 - US President Donald Trump’s threat to bring forward planned tariffs of up to 200% on pharmaceuticals ...